EPCAM and cancer: Moreover, the expression of neoantigens of EpCAM+ cancer cells in MPE should be monitored during disease progression, because a decreased CD8+ T cell response to SMAD4P130L might occur due to the loss of the SMAD4P130L antigen in MPE2nd.